Covered recipient · General Payments record
LESLIE BRYAN FORGOSH
Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$37.62
2 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $37.62 | 2 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Boston Scientific Corporation | $22.67 | 1 |
| Amgen Inc. | $14.95 | 1 |
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LESLIE BRYAN FORGOSH
NPI 1154305738 · CMS profile ID 278624
Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease
SAINT PAUL, MN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1154305738?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LESLIE BRYAN FORGOSH, NPI 1154305738, CMS profile ID 278624. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154305738?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). LESLIE BRYAN FORGOSH, NPI 1154305738, CMS profile ID 278624. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154305738?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- LESLIE BRYAN FORGOSH, NPI 1154305738, CMS profile ID 278624, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1154305738?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
2 matching records · $37.62 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–2 of 2.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Boston Scientific Corporation | $22.67 | 12/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662643119 | CMS |
| Amgen Inc. | $14.95 | 02/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662637654 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $2,031.09 | 11 |
| PY2025 | Principal investigator | $1,145,528.44 | 27 |
| PY2024 | Principal investigator | $1,362,432.04 | 31 |
| PY2023 | Recipient | $140.82 | 1 |
| PY2023 | Principal investigator | $1,104,464.55 | 33 |
| PY2022 | Recipient | $3,197.00 | 1 |
| PY2022 | Principal investigator | $739,768.96 | 53 |
| PY2021 | Recipient | $4,441.01 | 1 |
| PY2021 | Principal investigator | $667,326.41 | 59 |
| PY2020 | Recipient | $6,717.97 | 2 |
| PY2020 | Principal investigator | $475,435.63 | 71 |
| PY2019 | Principal investigator | $661,892.22 | 89 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
38 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Recipient | Regeneron Pharmaceuticals, Inc. | $70.00 | 12/23/2025 | Covered Recipient Physician | A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) | No dispute reported | 06/30/2026 | 1184117579 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $71.63 | 12/23/2025 | Covered Recipient Physician | A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) | No dispute reported | 06/30/2026 | 1184117581 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $11,450.00 | 12/15/2025 | Covered Recipient Teaching Hospital Healtheast St Josephs Hospital | HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190297208 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $339.78 | 12/06/2025 | Covered Recipient Physician | A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) | No dispute reported | 06/30/2026 | 1184117565 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $609.76 | 12/06/2025 | Covered Recipient Physician | A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) | No dispute reported | 06/30/2026 | 1184117567 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $89.89 | 12/06/2025 | Covered Recipient Physician | A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) | No dispute reported | 06/30/2026 | 1184117569 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $41.49 | 12/06/2025 | Covered Recipient Physician | A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) | No dispute reported | 06/30/2026 | 1184117571 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $110.63 | 12/06/2025 | Covered Recipient Physician | A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) | No dispute reported | 06/30/2026 | 1184117573 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $41.49 | 12/06/2025 | Covered Recipient Physician | A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) | No dispute reported | 06/30/2026 | 1184117575 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $88.50 | 12/06/2025 | Covered Recipient Physician | A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) | No dispute reported | 06/30/2026 | 1184117577 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $131.30 | 12/05/2025 | Covered Recipient Physician | A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) | No dispute reported | 06/30/2026 | 1184117563 |
| Principal investigator 1 | Boston Scientific Corporation | $4,201.40 | 11/18/2025 | Covered Recipient Teaching Hospital University Of Minnesota Medical Ctr | LUX-DX TRENDS | No dispute reported | 06/30/2026 | 1207572519 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,330.00 | 11/13/2025 | Covered Recipient Teaching Hospital University Of Minnesota Medical Ctr | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | No dispute reported | 06/30/2026 | 1175235062 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $436.62 | 11/07/2025 | Covered Recipient Physician | A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) | No dispute reported | 06/30/2026 | 1184117561 |
| Principal investigator 1 | Amgen Inc. | $2,454.42 | 10/08/2025 | Non-covered Recipient Entity M HEALTH FAIRVIEW ST. JOHN'S HOSPITAL | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246643727 |
| Principal investigator 1 | Amgen Inc. | $2,121.05 | 10/08/2025 | Non-covered Recipient Entity ST JOHNS HOSPITAL | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) | No dispute reported | 06/30/2026 | 1246648613 |
| Principal investigator 1 | Eli Lilly and Company | $312.00 | 09/24/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF MINNESOTA | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187888766 |
| Principal investigator 1 | Amgen Inc. | $72,875.00 | 09/23/2025 | Covered Recipient Teaching Hospital University Of Minnesota Medical Ctr | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) | No dispute reported | 06/30/2026 | 1246637806 |
| Principal investigator 1 | Amgen Inc. | $49,275.00 | 09/20/2025 | Non-covered Recipient Entity HEALTHEAST MEDICAL RESEARCH INSTITUTE | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246642154 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $11,537.56 | 09/15/2025 | Non-covered Recipient Entity FAIRVIEW HEALTH SERVICES | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190309868 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $17,385.00 | 09/02/2025 | Covered Recipient Teaching Hospital University Of Minnesota Medical Ctr | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190294637 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $80,134.98 | 08/19/2025 | Non-covered Recipient Entity FAIRVIEW HEALTH SERVICES | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190309862 |
| Principal investigator 1 | Amgen Inc. | $16,953.87 | 07/31/2025 | Non-covered Recipient Entity FAIRVIEW HEALTH SERVICES M HEALTH FAIRVIEW ST JOHNS HOSPITAL | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) | No dispute reported | 06/30/2026 | 1246641345 |
| Principal investigator 1 | Amgen Inc. | $34,772.12 | 07/20/2025 | Non-covered Recipient Entity FAIRVIEW HEALTH SERVICES M HEALTH FAIRVIEW ST JOHNS HOSPITAL | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246641347 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,178.00 | 04/30/2025 | Non-covered Recipient Entity Fairview Health Services | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fracti | No dispute reported | 06/30/2026 | 1225406022 |
| Principal investigator 1 | Amgen Inc. | $90,767.00 | 04/24/2025 | Covered Recipient Teaching Hospital University Of Minnesota Medical Ctr | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246637804 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $89,825.28 | 02/21/2025 | Covered Recipient Teaching Hospital University Of Minnesota Medical Ctr | A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function | No dispute reported | 06/30/2026 | 1185540029 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,958.60 | 02/20/2025 | Non-covered Recipient Entity FAIRVIEW HEALTH SERVICES | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190308082 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $288,090.60 | 02/17/2025 | Covered Recipient Teaching Hospital Healtheast St Josephs Hospital | HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190294584 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $51,543.44 | 02/04/2025 | Non-covered Recipient Entity FAIRVIEW HEALTH SERVICES | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190308080 |
| Principal investigator 1 | Eli Lilly and Company | $2,601.59 | 01/27/2025 | Non-covered Recipient Entity HEALTHEAST MEDICAL RESEARCH INSTITUTE | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187883200 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $45,404.18 | 01/27/2025 | Non-covered Recipient Entity FAIRVIEW HEALTH SERVICES | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190309864 |
| Principal investigator 1 | Eli Lilly and Company | $44,460.50 | 01/21/2025 | Non-covered Recipient Entity HEALTHEAST MEDICAL RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187880195 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,000.00 | 01/17/2025 | Covered Recipient Teaching Hospital University Of Minnesota Medical Ctr | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | No dispute reported | 06/30/2026 | 1175234836 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $369.41 | 01/15/2025 | Non-covered Recipient Entity FAIRVIEW HEALTH SERVICES | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190309870 |
| Principal investigator 1 | Amgen Inc. | $57,787.04 | 01/14/2025 | Non-covered Recipient Entity FAIRVIEW HEALTH SERVICES M HEALTH FAIRVIEW ST JOHNS HOSPITAL | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246641343 |
| Principal investigator 1 | Eli Lilly and Company | $116,082.00 | 01/07/2025 | Non-covered Recipient Entity HEALTHEAST MEDICAL RESEARCH INSTITUTE | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187881396 |
| Principal investigator 1 | Amgen Inc. | $36,658.40 | 01/02/2025 | Non-covered Recipient Entity HEALTHEAST MEDICAL RESEARCH INSTITUTE | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke | No dispute reported | 06/30/2026 | 1246642149 |